Mylan To Appeal Lorazepam, Clorazepate Antitrust Decision Awarding $35.9 Million In Damages
This article was originally published in The Pink Sheet Daily
Executive Summary
In the last of pending antitrust cases related to lorazepam and clorazepate monopoly, D.C. district court orders Mylan to pay $35.9 million to health insurers.